Antimalarial medication multi-drug resistant "P. falciparum". It is a very potent blood schizonticide with a long half-life. It is thought to act by forming toxic heme complexes that damage parasitic food vacuoles. Mefloquine is effective in prophylaxis and for acute therapy. It is now used solely for the prevention of resistant strains of "P. falciparum" (usually combined with Artesunate) despite being effective against "P. vivax", "P. ovale" and "P. marlariae". Chloroquine/proguanil or sulfa drug-pyrimethamine combinations should be used in all other plasmodia infections. The major commercial manufacturer of mefloquine-based malaria treatment is Roche Pharmaceuticals, which markets the drug under the trade name
Alternative treatments used for the common cold children by 18%. Vitamin C also decreased the severity of colds. A systematic review by the Cochrane Collaboration, last updated in 2014, examines twenty-four randomized controlled trials studying various echinacea preparations for prevention and treatment of the common cold. Echinacea showed no benefit over placebo for prevention. Evidence for treatment was inconsistent. Reported side effects were rare. 2007 meta-analyses conclude that there is some evidence that echinacea may reduce either the duration or severity of the common cold, but results are not consistent. Use of echinacea preparations is not currently recommended. In the twelfth century, Moses Maimonides wrote, "Chicken soup